SCHEMBL4088676

SCHEMBL4088676

CC(C)(C)OC(=O)Oc1ccc(NC(=O)c2nc(C(Cl)(Cl)Cl)n(-c3ccccc3)n2)c(Cl)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
MAPT P10636 8/20 0.39
KDM4E B2RXH2 4/20 0.39
NPSR1 Q6W5P4 3/20 0.39
HPGD P15428 3/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
ALDH1A1 P00352 3/20 0.38
TDP1 Q9NUW8 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
LMNA P02545 3/20 0.37
TP53 P04637 1/20 0.36
NR3C1 P04150 1/20 0.36
MAPK14 Q16539 1/20 0.36
MITF O75030 1/20 0.36
KLF5 Q13887 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GAA P10253 1/20 0.36
ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4015076 0.81 POLB (0.46) POLBMAPTKDM4ENPSR1HPGD
SCHEMBL4010350 0.80 MAPT (0.49) POLBMAPTKDM4ENPSR1HPGD
SCHEMBL4088650 0.75 POLB (0.40) POLBMAPTKDM4ENPSR1HPGD
SCHEMBL13901654 0.74 POLB (0.48) POLBMAPTKDM4ENPSR1HPGD
SCHEMBL4083462 0.74 CA1 (0.43) POLBMAPTKDM4ENPSR1ALDH1A1
SCHEMBL13901656 0.73 S1PR5 (0.43) POLB
SCHEMBL13901607 0.72 CYP2C19 (0.41) MAPTKDM4ENPSR1HPGDCYP2C9
SCHEMBL13901918 0.72 CA1 (0.42) POLBMAPTKDM4ENPSR1HPGD
SCHEMBL4088640 0.72 MAPK14 (0.44) POLBMAPTKDM4ENPSR1HPGD
SCHEMBL13901659 0.70 S1PR1 (0.41) POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069288-A1 Novel therapeutic compounds ABBVIE INC. 2009-03-12 US disclosed
US-20090069288-A1 Novel therapeutic compounds ABBVIE INC. 2009-03-12 US disclosed
US-20090069288-A1 Novel therapeutic compounds ABBVIE INC. 2009-03-12 US disclosed
WO-2009011850-A2 NOVEL THERAPEUTIC COMPOUNDS ABBOTT LABORATORIES (US) 2009-01-22 WO disclosed
WO-2009011850-A2 NOVEL THERAPEUTIC COMPOUNDS ABBOTT LABORATORIES (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069288-A1 Novel therapeutic compounds MAP3K20, RPS6KB1, MAP3K1 POLB 1544/4885MAPT 3755/4885KDM4E 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.